Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of FE 999301 (Olamkicept) in Healthy Japanese Men
NCT06515834Phase 1Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Nov 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD) comparing FE 999301 with Placebo (2 arms). Primary endpoints: Number of treatment-emergent adverse events, Blood pressure, Pulse, Body temperature, Heart rate and 2 more. Started Jul 2024; status: completed.
02
Drugs
olamkicept
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06515834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515834.